Status:

UNKNOWN

Oxygen Assist Module in Preterm Infants on High Flow Nasal Cannula Support.

Lead Sponsor:

South Tees Hospitals NHS Foundation Trust

Collaborating Sponsors:

Vapotherm, Inc.

Conditions:

Preterm Birth

Eligibility:

All Genders

23-32 years

Phase:

NA

Brief Summary

Oxygen treatment is common in babies born early (preterm) and requiring intensive care. Having too much or too little oxygen can increase the risk of damage to the eyes and lungs, and contribute to de...

Detailed Description

Supplemental oxygen remains by far the most commonly used 'drug' in neonatal intensive care units. The goal of oxygen therapy is to maintain normal oxygenation while minimizing hypoxemia and hypoxemia...

Eligibility Criteria

Inclusion

  • Preterm infants {born at a gestation \<33 weeks (23+0 to 32+6 weeks) }
  • Receiving HFNC as respiratory support anytime during their stay in the neonatal support

Exclusion

  • Preterm infants more than equal to 33 weeks.
  • Preterm infants with major congenital or chromosomal anomalies

Key Trial Info

Start Date :

April 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2023

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04687618

Start Date

April 15 2021

End Date

April 30 2023

Last Update

April 27 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

James Cook University Hospital

Middlesbrough, United Kingdom, TS4 3BW